Use of cannabidiol in the treatment of epilepsy
US11400055B2 · kind B2 · utility
25Cited by
19References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2021 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Jun 7, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.